Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:CASNumber |
gptkb:1229705-06-9
|
| gptkbp:clinicalTrialPhase |
Phase 1
Phase 2 |
| gptkbp:developedBy |
gptkb:Roche
|
| gptkbp:hasInChIKey |
QJQYJZKZBOVQJZ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C31H29Cl2F2N3O4
|
| gptkbp:hasSMILES |
CC1=CC(=O)N(C2=CC=CC=C12)C3=CC=C(C=C3)C4=NC5=C(C(=C(N4)Cl)Cl)C(=O)N(C5=O)C6=CC=C(C=C6)F
|
| gptkbp:hasTargetDisease |
gptkb:acute_myeloid_leukemia
solid tumors hematological malignancies |
| gptkbp:hasUNII |
6Z1Y2V4S2E
|
| https://www.w3.org/2000/01/rdf-schema#label |
RG7388
|
| gptkbp:intendedUse |
anticancer agent
|
| gptkbp:mechanismOfAction |
MDM2 inhibitor
|
| gptkbp:molecularWeight |
632.5 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3544943
46215522 |
| gptkbp:restoresFunctionOf |
gptkb:p53_protein
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
gptkb:idasanutlin
gptkb:RO5503781 |
| gptkbp:target |
gptkb:MDM2_protein
|
| gptkbp:therapeuticArea |
oncology
|
| gptkbp:bfsParent |
gptkb:idasanutlin
|
| gptkbp:bfsLayer |
7
|